Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) activate G protein-18 coupled receptors (GPCRs) to regulate key pathobiological processes. Here we report a novel 19 lipid mediator GPCR cross-talk mechanism that modulates lymphatic endothelial junctional 20 architecture in lymph nodes. LPAR1 was identified as an inducer of S1PR1/ ß-arrestin coupling 21 from a genome-wide CRISPR/ Cas9 transcriptional activation screen. LPAR1 activation induced 22 S1PR1 ß-arrestin recruitment while suppressing Gαi protein signaling. Lymphatic endothelial 23 cells from cortical and medullary sinuses of lymph nodes which express LPAR1 and S1PR1, 24 exhibit porous junctional architecture and constitutive S1PR1 coupling to ß-arrestin which was 25 suppressed by the LPAR1 antagonist AM095. In endothelial cells, LPAR1-activation increased 26 trans-endothelial permeability and junctional remodeling from zipper-like structures to puncta of 27 adhesion plaques that terminate at actin-rich stress fibers with abundant intercellular gaps. Cross-28 talk between LPA and S1P receptors regulates complex junctional architecture of lymphatic sinus 29 endothelial cells, a site of high lymphocyte traffic and lymph flow. 30 signaling in neuronal and immune systems (19, 20). A key question that is raised by such findings 54 is whether LPA and S1P are redundant in their biological functions. Data available so far suggest 55 that while some redundant functions are mediated by both LPA and S1P, some unique functions 56 do exist. For example, naïve T cell egress from secondary lymphoid organs is largely dependent 57 on S1P signaling on lymphocyte S1PR1 (21) whereas both LPA and S1P induce fibrotic responses 58 in the lung (22) as well as regulate cardiac development in zebrafish (23). Whether LPA and S1P 59 signaling mechanisms regulate each other (i.e. crosstalk mechanisms) is not known. 60
Introduction 31
Membrane phospholipids are rapidly metabolized by lipases and synthases to maintain the 32 integrity of biological membranes (1) . Lysophospholipids, which are metabolic intermediates, 33 have unique geometry and biophysical properties that facilitate membrane topology, vesicle 34 budding and fusion (2). However, lysophospholipids evolved as extracellular lipid mediators in 35 vertebrates (3). The best characterized are lysophosphatidic acid (LPA) and sphingosine 1-36 phosphate (S1P), structurally-related lysophospholipids which were originally identified as major 37 regulators of cellular cytoskeletal dynamics (4-6). LPA, which is synthesized in the extracellular 38 environment by autotaxin-mediated hydrolysis of lysophosphatidyl choline, activates six G-39 protein-coupled receptors (GPCRs) in the EDG and purinergic subfamilies (7) . S1P, on the other 40 hand, is synthesized largely in the intracellular environment and secreted via specific transporters 41 SPNS2 and MFSD2B (8) (9) (10) (11) . Extracellular chaperone-bound S1P activates five GPCRs in the 42 EDG subfamily that are widely expressed (8) . 43
Both LPA and S1P were originally identified as bioactive lipid mediators due to their 44 ability to modulate cytoskeletal dynamics, neurite retraction, cell migration, cell proliferation, and 45 intracellular ion changes (6). Such activity depends on the ability of LPA and S1P to regulate Rho 46 family GTPases (12) . After the discovery of the GPCRs for LPA and S1P, genetic loss of function 47 studies in the mice have identified their essential roles in embryonic development and 48 physiological processes of multiple organ systems (13). For example, both LPA and S1P signaling 49 was shown to be important in early vascular development since mice that lack autotaxin (Enpp2) 50 as well as sphingosine kinases (Sphk1 and 2) were embryonic lethal at early stages of gestation 51 (14-16). Similarly, compound S1P and LPA receptor knockouts also exhibit severe vascular 52 development defects (17, 18) . Similar studies have implicated the critical roles of S1P and LPA 53
Results 71
Unbiased, genome-wide search for S1PR1 modulators 72 S1PR1 signaling can be readily monitored by ligand-activated ß-arrestin coupling to the 73 GPCR by the TANGO system, which leads to nuclear fluorescent protein expression (30). This 74 system was shown to be sensitive to receptor activation in transfected cell lines and in the mouse. 75
Since the receptor/ ß-arrestin coupling is faithfully registered and is cumulative due to the stability 76 of the nuclear fluorescent protein, we adapted this system to U2OS osteosarcoma cells that are 77 adaptable to high-throughput screening. Previous work has shown that direct activators of S1PR1, 78 such as CD69 regulate receptor signaling and function (31) . In order to search for other 79 endogenous modulators of S1PR1 signaling, we turned to the synergistic activation mediator 80 (SAM) system that uses CRISPR/ Cas9-based, sgRNA-dependent transcriptional activation of 81 endogenous genes (32) . 82
The SAM system turns on endogenous gene expression by sgRNA-dependent recruitment 83 of multiple transcriptional activators (VP64, p65, and HSF1) at upstream of transcription start sites 84 via MS2 bacteriophage coat proteins and mutated Cas9. This screening system was validated by 85 the SAM sgRNA targeting SPNS2, an S1P transporter which functions at upstream of S1P 86 receptors (33, 34) . The designed SPNS2 SAM sgRNA induced 180-fold increase in its mRNA 87 expression and strongly activated the S1PR1-TANGO signal (Supplemental Figure 1) . 88
To carry out unbiased search for S1PR1-signaling modulators, the SAM sgRNA library 89 was introduced into S1PR1-TANGO system, in which ß-arrestin2 coupling of S1PR1 can be 90 monitored as nuclear expression of Venus fluorescent protein. Venus-positive cells (S1PR1/ ß-91 arrestin2 signaling positive) were sorted and expanded twice, genomic DNAs were purified and 92 sequenced by Illumina next-gen sequencing ( Figure 1A ). Bioinformatic analysis indicated that 93 some SAM sgRNA sequences are highly enriched in the Venus-positive cells after sorting ( Figure  94 1B). The LPAR1 gene was identified as one of the top hits from statistical analysis ( Figure 1C ). 95
Top ten candidates were individually examined by specific SAM sgRNAs that were enriched after 96 sorting Venus-positive cells. The SAM sgRNA specific for LPAR1 induced its expression and 97 turned on Venus expression, thus confirming the results from the genome-wide sgRNA screen that 98 identified LPAR1 as an S1PR1 modulator (Supplemental Figure 2) . 99
100

LPAR1 activation induces ß-arrestin recruitment to S1PR1 101
To further investigate the mechanisms involved in the regulation of S1PR1 signaling by 102 LPAR1, we used the NanoBiT system (35). This system is based on the structural 103 complementation of NanoLuc luciferase and allows one to monitor the protein-protein interactions 104 in real-time. NanoLuc luciferase is split into a small subunit (SmBiT; 11 amino acids) and a large 105 subunit (LgBiT; 18kDa), that are fused with S1PR1 and ß-arrestin1 with mutations in AP-2/ 106
Clathrin-binding motif (to reduce endocytosis), respectively ( Figure 2A ). S1P dose-dependently 107 stimulated ß-arrestin1 recruitment to S1PR1 in HEK293A cells transfected with S1PR1-SmBiT 108
and LgBiT-ß-arrestin1 ( Figure 2B ). LPA treatment did not induce ß-arrestin1 recruitment to 109 S1PR1, consistent with the fact that LPA is not a high affinity ligand for S1PR1 (36, 37) . However, 110 in cells co-expressing LPAR1 and S1PR1-SmBiT, LPA treatment induced ß-arrestin1 recruitment 111 to S1PR1 with an EC50 of ~ 10 -7 M, which is a physiologically-relevant concentration of LPA 112 ( Figure 2C) . 113
The effect of LPA was completely blocked by Ki16425, an LPAR1 antagonist(38) , 114
indicating that the ß-arrestin1 coupling of S1PR1 is dependent on LPAR1 activation by the ligand 115 ( Figure 2D ). W146, an S1PR1 antagonist, inhibited S1P-mediated ß-arrestin1 recruitment to 116 In many GPCRs, ß-arrestin recruitment is an initial trigger for receptor internalization by 162 facilitating interaction with AP-2 and clathrin, that help recruit the GPCRs to the endocytic 163 machinery (45). S1PR1 tagged with Flag at extracellular N-terminal was expressed in HEK293A 164 cells with LPAR1 and Flag-S1PR1 cell surface expression was analyzed by flow cytometry. 165
Surprisingly, Flag-S1PR1 surface expression was not changed by LPA stimulation while S1P 166 stimulation induced Flag-S1PR1 internalization ( Figure 5A ). Immunofluorescence analysis 167 confirmed these conclusions (Supplemental Figure 6 ). These results suggest that while LPAR1-168 induced inter-GPCR ß-arrestin coupling to S1PR1, this event in and of itself is not sufficient to 169 induce S1PR1 endocytosis. 170
Next, we examined whether LPAR1 activation modulates the S1PR1 signal transduction. 171
Coupling of S1PR1 to the heterotrimeric G protein pathway was assessed using LgBiT-GNAO1/ 172
SmBiT-GNG and AUY954, an S1PR1 selective agonist (46). AUY954 induced S1PR1-mediated 173 heteromeric G protein dissociation in a dose dependent manner, and that was significantly 174 suppressed by co-expression with LPAR1 ( Figure 5B ). Other LPA receptors (LPAR2 and LPAR5) 175 expressed at similar levels as LPAR1 failed to suppress S1PR1-mediated Gai protein activation 176 ( Figure 5B and C). These results indicate that LPAR1 specifically induces inter-GPCR ß-arrestin 177 coupling to suppress S1PR1 heterotrimeric Gai protein signaling pathway without inducing 178 receptor endocytosis. 179 180
Endogenous LPAR1 stimulates S1PR1/ ß-arrestin coupling in vivo at lymphatic sinuses 181
Next, to examine whether endogenously-expressed LPAR1 induces inter-GPCR ß-arrestin 182 coupling to S1PR1, we isolated mouse embryonic fibroblast (MEF) cells from S1PR1 luciferase 183 signaling mice, in which endogenous S1PR1/ ß-arrestin2 coupling can be monitored via the firefly 184 split luciferase fragment complementation system (47). As shown in Figure 6A , LPA induced the 185 S1PR1/ ß-arrestin2 coupling in a dose dependent manner, that was blocked by Ki16425, indicating 186 that the activation of endogenously-expressed LPAR1 induces inter-GPCR ß-arrestin coupling to 187 S1PR1. 188 S1PR1 luciferase signaling mice were used to determine if LPAR1-induced inter-GPCR ß-189 arrestin coupling to S1PR1 occurs in vivo. As previously observed, significant S1PR1 coupling to 190 ß-arrestin is seen in several organs in normal mice under homeostatic conditions (47) of S1PR1 in vitro ( Figure 6B ). Administration of AM095 to S1PR1 luciferase signaling mice 194 significantly decreased bioluminescence signals ( Figure 6C -E). Detailed imaging of dissected 195 mice showed that S1PR1 coupling to ß-arrestin in lung, spleen, and lymph nodes were all 196 significantly attenuated by AM095 treatment ( Figure 6F -H). 197
Since lymphatic endothelial cells express both LPAR1 and S1PR1 (49), we further 198 examined the in vivo relevance of LPAR1-induced inter-GPCR ß-arrestin coupling to S1PR1 in 199 murine lymph nodes under homeostatic conditions. For this, we used S1PR1-GFP signaling mouse 200 which records cumulative S1PR1 coupling to ß-arrestin while allowing high resolution imaging 201 studies (30). Immunofluorescence and confocal microscopy of brachial lymph node sections in 202 adult mice showed strong S1PR1 coupling to ß-arrestin in lymphatic endothelial cells that make 203 up cortical, medullary, and subcapsular sinuses ( Figure 7A ). As previously reported (30), high 204 endothelial venules (HEV) also exhibit S1PR1 coupling to ß-arrestin (Supplemental Figure 7) . 205
When mice were treated with the LPAR1 inhibitor AM095 for 5 days, S1PR1-GFP signal in 206 subcapsular sinuses and HEV were not altered ( Figure 7B ,C, and Supplemental Figure 7 ). In 207 contrast, S1PR1-GFP signal inside the lymph nodes, which are mostly from lymphatic endothelial 208 cells of cortical and medullary sinuses, were suppressed ( Figure 7D and E). These data are 209 consistent with quantitative imaging data using S1PR1 luciferase signaling mice shown above and 210 strongly suggest that the site of LPAR1-induced inter-GPCR ß-arrestin coupling to S1PR1 is at 211 the lymphatic endothelial cells of inter-lymphatic sinuses in vivo. High resolution images of cell-212 cell junctions in sinus lining endothelial cells of lymph nodes is shown in Figure 7F . The junctional 213 structure is complex and contains both continuous and punctate VE-cadherin and PECAM-1 214 positive structures. 215
216
LPAR1 activation suppresses endothelial barrier function and junctional architecture 217
Lymphatic endothelial cells of sinuses in lymph nodes exhibit complex junctional 218 architecture consisting of button-like structures and high permeability of lymph flow, which are 219 thought to be important for efficient lymphocyte egress and lymphatic fluid drainage and flow (50, 220 51). Further, endothelial S1PR1 regulates vascular barrier function by activating Gαi/ Rac GTPase 221 signaling pathway that stimulates VE-cadherin assembly at adherens junctions (52). To examine 222 whether LPAR1 modulates S1PR1-dependent barrier function in endothelial cells, LPAR1 was 223 expressed in HUVEC using an inducible system (Supplemental Figure 8 ) and the barrier function 224 was quantified by measuring trans-endothelial electrical resistance (TEER) (53). As expected, 225 S1PR1 agonist AUY954 induced sustained increase in vascular barrier function ( Figure 8A ). LPA 226 itself did not influence barrier function either in the presence or absence of AUY954 ( Figure 8A ). 227
However, in HUVEC expressing LPAR1, LPA-induced a small and transient increase in barrier 228 function ( Figure 8C ). In sharp contrast, LPA inhibited AUY954-induced vascular barrier increase 229 significantly ( Figure 8C ). This was completely reversed by Ki16425, an antagonist of LPAR1 230 ( Figure 8D ). These data suggest that LPAR1 induces inter-GPCR ß-arrestin coupling to attenuate 231 S1PR1-induced barrier function and thereby enhance the porosity of the endothelial monolayer. 232
In order to determine the cellular changes induced by LPAR1 and S1PR1 inter-GPCR ß-233 arrestin coupling, we examined the status of VE-cadherin, a major junctional protein. F-actin and 234 p-MLC (phospho-myosin light chain) were also examined to determine the role of Rho-coupled 235 actin/ myosin architecture which is known to be downstream of LPAR1 (54). As anticipated, 236 S1PR1 activation by AUY954 strongly induced junctional VE-cadherin ( Figure 8E and F). In 237 S1PR1 activated HUVEC, minimal intercellular gaps were observed and VE-cadherin appeared as 238 continuous, zipper-like structures at cell-cell borders ( Figure 8F ). Cortical F-actin was induced 239 and p-MLC staining was attenuated, suggesting increase in Rac GTPase and decrease in Rho 240
GTPase activity, respectively ( Figure 8E and F). LPA treatment strongly induced intercellular 241 gaps which punctuate continuous VE-cadherin staining, strong F-actin staining and stress fibers 242 and marked increase in p-MLC staining ( Figure 8G ). In the presence of both LPA and AUY954, 243 junctional architecture was modulated to contain a hybrid of continuous cell-cell border staining 244 interspersed with punctate VE-cadherin localization at the termini of actin stress fibers ( Figure  245 8H). p-MLC and F-actin at stress fibers was slightly attenuated ( Figure 8G and H). However, 246 intercellular gaps were induced when compared with S1PR1 activated HUVEC ( Figure 8F and H). 247
These results suggest that the LPAR1 activation induces inter-GPCR ß-arrestin coupling to S1PR1 248 which modulates Rho GTPase-coupled signal transduction pathways to allow complex cell-cell 249 adherens junction architecture and decreased vascular barrier function. Similar cellular 250 mechanisms may occur in lymphatic endothelial sinuses to regulate high lymphocyte traffic and 251 efficient lymphatic fluid flow. 252
253
DISCUSSION 254
A major finding of this study is that LPAR1 directly regulates S1PR1 function. This 255 constitutes a heretofore undescribed cross-talk mechanism between LPA and S1P, two 256 lysophospholipids which acquired extracellular functions as vertebrates evolved (3). As 257 vertebrates acquired closed vascular systems, immune cells which are now faced with the 258 challenge of navigating in and out of the circulatory system used S1P, an abundant circulatory 259 lipid mediator with defined spatial gradients for lymphocyte trafficking (21). Our present results 260 suggest that LPA signaling modulates S1PR1 signaling in specific contexts. The S1PR1 receptor 261 is expressed abundantly in endothelial cells and its cell surface expression is controlled by multiple 262 processes (55). For example, the lymphocyte activation-induced molecule CD69 directly interacts 263 with S1PR1 to induce its ligand-dependent endocytosis, a process that decides whether 264 lymphocytes egress occurs or not (24, 31) . Indeed, tissue residency of various T cells is controlled 265 by CD69 (31). In endothelial cells, cell surface signaling of S1PR1 regulates vascular barrier 266 function (52, 56). Thus, our finding that LPAR1 modulates S1PR1 directly suggests functional 267 cross-talk between LPA and S1P. 268
Our study also provides a method to discover novel regulators of GPCR signaling. By 269 adapting a receptor reporter that induces GFP expression downstream of GPCR/ ß-arrestin-270 coupling with a whole genome-wide CRISPR/ Cas9-dependent transcriptional activation system, 271
we identified LPAR1 as a regulator of S1PR1 function. This system could be adapted to other 272 GPCRs or signaling pathways. Given the modularity and flexibility of CRISPR/ Cas9 system 273 which can both activate or repress genes (29), we suggest that many novel signaling proteins that 274 modulate GPCRs could be identified using similar screens. 275
We also describe in detail, mechanistic insight into interactions between S1PR1 and 276 LPAR1. S1PR1 and LPAR1 interaction requires the TM4 domain of S1PR1, which was 277 previously identified to be critical for direct interaction with CD69, an event critical for 278 lymphocyte egress (31). Activated LPAR1 recruits ß-arrestin which is then transferred to S1PR1, 279 a phenomenon that we refer to as inter-GPCR ß-arrestin coupling. Recent structural studies 280 indicate that both the C-terminal tail and the 3 rd intracellular loop of GPCRs are involved in direct 281 interaction with ß-arrestin (44). Since the 3 rd intracellular loop of S1PR1 interacts directly with 282
Gai family of heterotrimeric G proteins (57), inter-GPCR ß-arrestin signaling resulted in 283 attenuation of S1PR1/ Gai signaling. However, this mechanism is not sufficient to induce S1PR1 284 endocytosis. Thus, we suggest that LPAR1-induced inter-GPCR ß-arrestin coupling results in 285 suppression of signaling by plasma membrane-localized S1PR1. This may allow rapid reversal of 286 S1PR1 inhibitory activity and thus may allow acute regulatory mechanism for S1PR1 GPCR. 287
A key issue we addressed in this study is whether this phenomenon occurs in vivo. For 288 this, we turned to the recently-developed real-time S1PR1 luciferase signaling reporter mice, 289 which induces luciferase activity upon S1PR1/ ß-arrestin coupling (47). Our data show that 290 constitutive luciferase signal in the several organs of adult S1PR1 luciferase signaling reporter 291 mice is LPAR1-dependent. In particular, cervical and mesenteric lymph nodes showed strong 292 luciferase activity that was suppressed by LPAR1 antagonist AM095. High resolution confocal 293 microscopy studies show that sinus lining lymphatic endothelial cells in cortical and medullary 294 sinuses of lymph nodes are the cells in which inter-GPCR ß-arrestin coupling between LPAR1 and 295 S1PR1 occurs. Such structures are the sites at which many lymphocytes egress from the lymph 296 node parenchyma into the lumen of the sinuses (50, 51). In addition, lymph from afferent 297 lymphatics that permeate through the lymph node parenchyma flow through these sinus walls to 298 ultimately drain from the efferent lymphatic vessels. We suggest that inter-GPCR ß-arrestin 299 coupling between LPAR1 and S1PR1 regulates the specialized properties of lymph node sinus 300 lining endothelial cells. 301
It is noteworthy that S1P-dependent lymphocyte egress occurs at cortical and medullary 302 sinuses (58). S1P that is enriched in lymph that is secreted from lymphatic endothelial cells via 303 SPNS2-dependent processes (59, 60), together with low S1P in the lymphatic parenchymal spaces, 304 provides the spatial S1P gradient needed for efficient lymphocyte egress (21). Cell surface S1PR1 305 on lymphocytes detect this gradient for a spatial cue for the egress process which involves traverse 306 of the lymphocyte through the sinus lining endothelial cells (61). Once the lymphocytes have 307 entered the lumen of the cortical and medullary sinuses, ensuing lymph flow help drain them into 308 efferent lymphatic vessels (58), thus ensuring efficient lymphocyte trafficking. Our results suggest 309 that LPAR1-dependent inter-GPCR ß-arrestin coupling keeps the lymphatic endothelial cell 310 S1PR1 in an inactive state, which may be critical for homeostatic lymphocyte egress. It is 311 noteworthy that LPA is generated in the lymphoid tissue parenchyma (62) and regulate lymphocyte 312 motility and traffic within the lymph node (20, 63). 313
We addressed the role of LPAR1-induced inter-GPCR ß-arrestin coupling in endothelial 314 cell adherens junctions and barrier function. Our results show that this mechanism alters the 315 junctional architecture and decreases the endothelial barrier function. Specifically, junctions were 316 remodeled from continuous structures at cell-cell borders to punctate structures at the termini of 317 actin-rich stress fibers. This results in the formation of abundant intercellular gaps which explains 318 decreased vascular barrier function. Increased LPAR1-induced Rho GTPase pathways and 319 decreased S1PR1-induced Rac GTPase pathways are likely involved, as determined by the analysis 320 of downstream targets p-MLC and F-actin at the cell cortex and stress fibers, respectively (54, 64) . 321
We propose that junctional remodeling provides a mechanism for high permeability seen in sinus 322 lining lymphatic endothelial cells of lymph nodes. Previous studies in lymphatic endothelial cell 323 junctions have described the presence of button-like junctions which are actively maintained in 324 lymph nodes (51) and in lymphatic capillaries of the small intestinal villi (65). Indeed, this 325 property may allow lymph fluid flow and efficient lymphocyte egress under physiological 326 conditions. 327
In summary, we have described a mechanism via which LPAR1 suppresses cell surface 328 S1PR1/ Gai signaling by inter-GPCR ß-arrestin coupling. This process regulates lymphatic 329 endothelial cell junctional architecture and barrier function at sinus lining endothelial cells under 330 physiological conditions. Cross-talk between LPA and S1P receptors regulates complex functions 331 of circulatory and immune systems. Pharmacologic modulation of this pathway may be useful in 332 lymphatic and immune disorders. 333
Materials and methods 334
Reagents 335
Primary antibodies used in this study include the following: PE rat monoclonal anti-Flag 336 tag (L5), Alexa Fluor 647 mouse monoclonal anti-HA (16B12), Alexa Fluor 647 rat monoclonal 337
CD8a (53-6.7), Alexa Fluor 647 rat monoclonal CD169 (3D6.112), Alexa Fluor 594 rat 338 monoclonal B220 (RA3-6B2), Alexa Fluore 647 Armenian hamster monoclonal CD11c (N418) 339 (Corning) supplemented with 10% FBS and 1% penicillin-streptomycin in a 37 ºC incubator with 359 5% CO2. HUVECs were cultured in EGM-2 medium (Lonza) supplemented with 10% FBS or 360 M199 medium (Corning) supplemented with 10% FBS, penicillin-streptomycin, endothelial cell 361 growth factor from sheep brain extract, and 5 units/ml heparin on human fibronectin-coated dishes 362 in a 37 ºC incubator with 5% CO2. 363 364
Generation of U2OS cell line for library screening 365
The U2OS cells transduced with dCas9-VP64 (a gift from Feng Zhang, Addgene #61425) 366
and MS2-P65-HSF (a gift from Feng Zhang, Addgene #61426) (32) were selected with 6 µg/mL 367 Blasticidin (Gibco) and 200 µg/mL Hygromycin (Gibco), respectively. For S1PR1-TANGO 368 system, mouse S1pr1 linked to tTA via a TEV protease cleavage site and mouse β-arrestin 2 linked 369 to TEV protease were designed to be cloned in a single vector using a bicistronic internal ribosome 370 entry site (IRES) as described previously (30), and the PCR amplicon from this vector was cloned 371 into pCDH-CMV-MCS-EF1α-Neo lentivector (System Biosciences) with Nhe I and Not I 372 digestion sites. The nuclear localization signal (NLS)-Venus (a gift from Karel Svoboda, Addgene 373 #15753 (66)) with PEST degradation sequence at C-terminal was cloned into downstream of TRE 374 site on pLVX-TetOn lentivector (Clontech). 600 µg/mL Geneticin (G418, Gibco) and 1 µg/mL 375 Puromycin (Gibco) were used for selecting the cells transduced with these constructs. 376
To produce lentiviral particles, HEK293T cells were seeded on 10 cm dishes 1 day before 377 transfection. On the following day when they had reached 80-90% confluency, medium was 378 replaced by fresh 10% FBS/DMEM medium one hour prior to transfection. 20 µg of lentiviral 379 plasmid, 12.6 µg of pMDL/pRRE, 9.6 µg of pVSV-G, and 6 µg of pRSV-REV were diluted with 380 water and mixed with 85.25 µl of 2M CaCl2 solution, then 688 µl of 2 × HBS solution (274 mM 381 NaCl, 1.5 mM Na2HPO4-7H2O, 55 mM HEPES, pH 7.0) was slowly added into the plasmids 382 solution while vortex. After incubation at room temperature for 20 min, the solution mixture was 383 added drop-wise directly to cells. Medium was replaced by 10% FBS/McCoy's 5A medium 12-384 16 hr after transfection. Lentiviral particle-containing supernatant was harvested at 2 days after 385 the medium change, and filtered with a 0.45 µm syringe filter (Corning). PEG-it Virus 386
Precipitation Solution (System Biosciences) was used when concentration was needed. U2OS 387 cells were seeded 1 day before infection. On the following day when they had reached 20-30% 388 confluency, medium was replaced by 10% FBS/McCoy's 5A medium containing lentiviral 389 particles. Medium was renewed 1 day after infection and antibiotics were added on the following 390 day. The single clones were isolated from antibiotics resistant cells by limiting dilution, then 391
introduced with the SAM sgRNA library (a gift from Feng Zhang, Addgene #1000000057) at a 392 low multiplicity of infection. 393
394
Library screening and sgRNA sequence analysis 395
The U2OS cells transduced with the SAM sgRNA library were cultured in 400 µg/ml 396 Zeocin (Gibco) to select cells harboring SAM sgRNAs. The Zeocin-resistant cells were allowed 397 to grow (pre-sort cells) or starved with 0.5% charcoal-treated FBS for 2 days. Then, starved cells 398 were harvested and Venus-positive cells were sorted by FACS (post-sort cells) as shown in Figure  399 1A. The sorted cells were seeded and expanded to repeat sorting. After second expansion, 400 genomic DNAs were harvested from 10 × 10 7 pre-and post-sort cells using the Quick-gDNA 401
MidiPrep (Zymo Research) according to the manufacturer's protocol. Amplification and 402 purification of genomic DNAs for NGS analysis was performed as described previously (67). 403
After quality control with Agilent 2200 TapeStation, libraries were subjected to single-end 404 sequencing on an Illumina NextSeq to generate at least 50 million reads for both pre-sort and post-405 sort cells. Reads were assigned to target genes using the previously described Python script 406 "count_spacers.py" with default parameters (67). The resultant count table was used as input for 407 the script "mageck" to generate significance scores for each target gene (68). Coelenterazine (Cayman) was added and incubated for 2 hr at room temperature in dark. Initial 440 luminescence was measured as baseline using SpectraMax L (Molecular Devices), then cells were 441 stimulated with ligands and incubated at room temperature. Luminescence after stimulation was 442 measured and normalized with initial reads. Development and validation of the NanoBiT-G 443 protein dissociation assay is described elsewhere (69). 444 445
Split firefly luciferase complementation assay in MEFs 446
MEFs isolated from S1PR1 luciferase signaling mice (47) were seed on a white 96 well 447 plate. On the following day, medium was replaced by 80 µl of 0.01% fatty acid free BSA/HBSS 448 supplemented with 5 mM HEPES and incubated for 2 hr at room temperature. 20 µl of 40 mg/mL 449 Luciferin (Perkin Elmer) was added and initial luminescence was measured. After stimulation 450 with LPA, luminescence was measured and normalized with initial reads. Bioluminescence in live 451 mice and internal organs was measured as described previously (47). 452 453
Generation of G protein alpha subunit-depleted HEK293 cells by CRISPR/ Cas9 system 454
G protein alpha subunit-depleted HEK293 cells were generated by mutating genes 455 encoding members of the Gαi family from previously established HEK293 cells devoid of three 456
Gα families (the Gαs, the Gαq, and the Gα12 families) (43), using CRISPR/ Cas9 system as 457 described previously (70, 71) with minor modifications. sgRNA constructs targeting the GNAI1, 458 the GNAI2, the GNAI3, the GNAO1, the GNAT1, the GNAT2, and the GNAZ genes, whose mRNA 459 were expressed in HEK293 cells (72) GATGCGGGTCAGCGAGTCGATGG-3′ (GNAZ; Hinf I). The designed sgRNA-targeting 471 sequences were inserted into the Bbs I site of the pSpCas9(BB)-2A-GFP (PX458) vector (a gift 472 from Feng Zhang, Addgene plasmid #42230) using a set of synthesized oligonucleotides as 473 following:
5′-CACCGCTTTGGTGACTCAGCCCGGG-3′ and 5′-474 AAACCCCGGGCTGAGTCACCAAAGC-3′ (GNAI1; note that a guanine nucleotide (G) was 475 introduced at the -21 position of the sgRNA (underlined), which enhances transcription of the 476 sgRNA); 5′-CACCGCGTAAAGACCACGGGGATCG-3′ and 5′-477
AAACCGATCCCCGTGGTCTTTACGC-3′
(GNAI2); 5′-478 CACCGAGCTTGCTTCAGCAGATCCA-3′ and 5′-AAACTGGATCTGCTGAAGCAAGCTC-479
3′
(GNAI3); 5′-CACCGAATCGCCTTGCTCCGCTCGA-3′ and 5′-480
AAACTCGAGCGGAGCAAGGCGATTC-3′
(GNAO1); 5′-481 CACCGTTTCAGGTGCCGGTGAGTCC-3′ and 5′-AAACGGACTCACCGGCACCTGAAAC-482
3′
(GNAT1); 5′-CACCGAACCATGCCTCCTGAGCTCG-3′ and 5′-483
AAACCGAGCTCAGGAGGCATGGTTC-3′
(GNAT2); 5′-484 CACCGATGCGGGTCAGCGAGTCGA-3′ and 5′-AAACTCGACTCGCTGACCCGCATC-3′ 485 (GNAZ). Correctly inserted sgRNA-encoding sequences were verified with a Sanger sequencing 486 (Fasmac, Japan) using a primer 5'-ACTATCATATGCTTACCGTAAC-3'. 487
To achieve successful selection of all-allele-mutant clone, we performed an iterative 488 CRISPR/ Cas9-mediated mutagenesis. Specifically, in the first round, mutations were introduced 489 in the GNAZ gene. In the second round, the GNAI2, the GNAI3, and the GNAO1 genes were 490 simultaneously mutated. In the last round, the GNAI1, the GNAT1, and the GNAT2 genes were 491 targeted. Briefly, the HEK293 cells devoid of three Gα families (43) were seeded into a 6 well 492 culture plate and incubated for one day before transfection. A plasmid encoding sgRNA and 493
SpCas9-2A-GFP was transfected into the cells using Lipofectamine® 2000 (ThermoFisher) 494 according to a manufacturer's protocol. Three days later, cells were harvested and processed for 495 isolation of GFP-positive cells (approximately 6% of cells) using a fluorescence-activated cell 496 sorter (SH800, Sony, Japan). After expansion of clonal cell colonies with a limiting dilution 497 method, clones were analyzed for mutations in the targeted genes by a restriction enzyme digestion 498 as described previously (43, 71) . PCR primers that amplify the sgRNA-targeting sites were as 499 following:
5'-AGCTGGTTATTCAGAAGAGGAGTG-3' and 5'-500 TGGTCCTGATAGTTGACAAGCC-3' (GNAI1); 5′-AAATGGCATGGGAGGGAAGG-3′ and 501 5′-TAAAACCTCAGTGGGGCTGG-3′ (GNAI2); 5′-AGCTGGCAGTGCTGAAGAAG-3′ and 5′-502 TCATACAAATGACCAAGGGCTC-3′ (GNAI3); 5′-GGTCCTTACCGAGCAGGAG-3′ and 5′-503 CGACATTTTTGTTTCCAGCCC-3′ (GNAO1); 5′-TAGGTGTGGCTACGGGGTC-3′ and 5′-504 GCACTCTTCCAGCGAGTACC-3′ (GNAT1); 5'-ACTGCTTCCATCTTAGGTCTTCG-3' and 505 5'-CATCAACCCACCCTCTCACC-3' (GNAT2); 5'-CGAAATCAAGCTGCTCCTGC-3' and 506 5'-TGTCCTCCAGGTGGTACTCG-3' (GNAZ). Candidate clones that harbored restriction 507 enzyme-resistant PCR fragments were further assessed for their genomic DNA alterations by 508 direct sequencing or TA cloning as described previously (43, 71) . 509 510
Measurement of endothelial barrier function in vitro 511
Endothelial barrier function was evaluated by measuring the resistance of a cell-covered 512 electrode by using an endothelial cell impedance system (ECIS) Zθ device (Applied BioPhysics) 513 in accordance with the manufacturer's instructions. Briefly, arrays were cleaned with 10 mM L-514 cysteine, washed with sterile water, coated with fibronectin for 30 minutes at 37 °C, and incubated 515 with complete cell culture medium to run electrical stabilization. HUVECs were seeded on a 96 516 well electrode array (96W10idf) at a density of 2.5 × 10 4 cells/well in the presence or absence of 517 1 µg/mL doxycycline. On the following, confluent cells were starved for 2-3 hr in EBM-2 (Lonza) 518 supplemented with 0.5% charcoal treated FBS, then stimulated with AUY954 and/ or LPA. 519
Resistance was monitored and expressed as fractional resistance, normalizing to the baseline at 520 time 0. 521 522 Imaging studies in mice 523 S1PR1-GFP or luciferase signaling mice have been previously described (30, 47) . 524
Bioluminescence image was acquired 2 hr after injection with vehicle (10 µM Na2CO3, 20% 2-525
Hydroxypropyl-ß-cyclodextrin) through gavage. Three hours after the first imaging for vehicle, 526 the AM095 (30 mg/kg) was administrated to the mice through gavage and bioluminescence image 527 was acquired 2 hr after injection. S1PR1-GFP signaling mice were injected with vehicle or AM095 528 (20 mg/kg, twice a day) for 5 days through gavage to collect lymph nodes. 529 530
Immunofluorescence staining 531
HUVECs were washed with cold PBS and fixed with 2% paraformaldehyde (PFA) for 10 532 min at room temperature. U2OS cell were washed with cold PBS and fixed with cold-methanol 533 for 10 min on ice. Lymph nodes were collected from mice perfused with cold PBS, fixed with 4% 534 PFA, and then embedded in the OCT compound (Sakura Finetek). Cells and cryosections were 535 permeabilized in 0.1% Triton X-100 for 20 min and incubated in blocking solution (75 mM sodium 536 chloride, 18 mM sodium citrate, 1% BSA, 2% FBS, 0.02% sodium azide, and 0.05% Triton X-537 100) for 1 hr, followed by incubation with primary antibodies for overnight at 4 ºC and with 538 secondary antibodies for 2 hr at room temperature. Images were visualized by confocal 539 microscopy using a Zeiss LSM 800. All presented images are 3D reconstructions of z-stack. 540
Immunoblot analysis 542
Cells were washed with cold-PBS and lysed in modified RIPA buffer (50 mM Tris (pH 543 7.4), 100 mM sodium chloride, 2 mM EDTA, 1% Triton X-100, 0.5% Fos-Choline, and 10 mM 544 sodium azide) containing phosphatase inhibitors (1 mM sodium orthovanadate, 1 mM sodium 545 fluoride, and 5 mM ß-glycerophosphate) and protease inhibitor cocktail (Sigma). After incubation 546 on ice for 30 min and a freeze/thaw cycle, protein concentrations in supernatant from 547 centrifugation at 10,000g, 15 min at 4 ºC were determined by bicinchoninic acid assay (Pierce), 548
and denatured for 30 min at room temperature in Laemmli's sample buffer supplemented with 549 10% ß-mercaptoethanol. An equal amount of proteins were loaded and separated on an SDS-550 polyacrylamide gel and transferred electrophoretically to polyvinylidene difluoride membrane 551 (Millipore). Transferred proteins were then probed with rabbit polyclonal anti-S1PR1 (Santa Cruz 552 Biotechnology) and HRP-conjugated goat anti-rabbit IgG (Jackson Immuno Research). 553 554 Flow cytometry analysis 555 U2OS cells, HEK293A cells, and HUVECs were detached with 0.05% Trypsin (Corning), 556 0.5 mM EDTA, and Accutase (Innovatice Cell Technologies), respectively. The harvested cells 557 were fixed with 1% PFA for 10 min on ice, and labeled with PE anti-Flag and Alexa Fluor 647 558 anti-HA antibodies for detecting cell surface expression. The samples were analyzed using BD 559
Calibur FACS system and FlowJo software was used for data analysis. (A) Schematic of NanoBiT system to measure S1PR1 and ß-arrestin1 interaction. SmBiT and 810
LgBiT were fused to C-terminal of S1PR1 and N-terminal of ß-arrestin, respectively. S1PR1 and 811 ß-arrestin1 coupling can be detected as luminescence signal emitted by complementation of 812
SmBiT and LgBiT. 813 (B) S1PR1-SmBiT or S1PR1(R120A)-SmBiT was transfected with LgBiT-ß-arrestin1, and 814 luminescence was measured at 15-20 min after S1P stimulation. 815 (C) LPAR1 or empty vector was transfected with S1PR1-SmBiT and LgBiT-ß-arrestin1, and 816 luminescence was measured at 15-20 min after LPA stimulation. 817 (D, E) The cells were incubated with 1 µM Ki16425 or W146 for 30 min prior to stimulation, and 818 luminescence was measured at 15-20 min after LPA (D) or S1P (E) stimulation. 819 (F) LPAR1 or empty vector was transfected with S1PR1(R120A)-SmBiT and LgBiT-ß-arrestin1, 820
and luminescence was measured at 15-20 min after LPA stimulation. SmBiT-GNGT1 plasmids with LPAR1 or LPAR1∆C. Luminescence was measured at 6-9 min 834 after LPA stimulation. 835 (C) LPAR1 or LPAR1∆C was transfected with S1PR1-SmBiT and LgBiT-ß-arrestin1, and 836 luminescence was measured at 15-20 min after LPA stimulation. 837 (D) S1PR1-SmBiT or S1PR1(TM4)-SmBiT was transfected with LgBiT-ß-arrestin1, and 838 luminescence was measured at 15-20 min after S1P stimulation. 839 (E) LPAR1 or empty vector was transfected with S1PR1-SmBiT or S1PR1(TM4)-SmBiT and 840
LgBiT-ß-arrestin1, and luminescence was measured at 15-20 min after LPA stimulation. 841 n = 3-5 independent experiments; expressed as mean ± SD. P values were determined by two-842 way ANOVA followed by Sidak's multiple comparisons test comparing "S1PR1(TM4)-SmBiT + 843 LPAR1" to "S1PR1-SmBiT + LPAR1"; *P = 0.0018, **P ≤ 0.001. expressing Flag-S1PR1 and LPAR1. 849 (B) S1PR1 and LPAR1, LPAR2, or LPAR5 were transfected with LgBiT-GNAO1, GNB1, and 850
SmBiT-GNGT1 plasmids. Luminescence was measured at 6-9 min after AUY954 stimulation. n 851 = 3-7 independent experiments; expressed as mean ± SD. P values were determined by two-way 852 ANOVA followed by Sidak's multiple comparisons test comparing "S1PR1 + LPAR1" to S1PR1 853 alone; *P ≤ 0.01, **P ≤ 0.0001. 854 (C) Flow cytometric analysis of HEK293A cells transfected with LPAR1 (orange), LPAR2 (brown 855 line), LPAR3 (dark green line) tagged with Flag at N-terminal, or empty vector (gray). 856 857
Figure 6. Endogenous LPAR1-induced inter-GPCR ß-arrestin coupling in vivo 858
(A) MEF cells isolated from S1PR1 luciferase signaling mice were added with luciferin, then 859 stimulated with LPA at various concentration in the presence or absence of 1 µM Ki16425. 860
Luminescence was measured at 8-12 min after LPA stimulation. n = 4 independent experiments; 861 expressed as mean ± SD. P values were determined by two-way ANOVA followed by Sidak's 862 multiple comparisons test comparing vehicle to Ki16425; *P = 0.0104, **P = 0.0021. 863 (B) LPAR1 was transfected with S1PR1-SmBiT and LgBiT-ß-arrestin1. The cells were incubated 864 with 1 µM AM095 for 30 min prior to stimulation, and luminescence was measured at 15-20 min 865 after LPA stimulation. 866 (C,D) Representative bioluminescence images of mice comparing the effects of vehicle (B) or 867 AM095 (30 mg/kg, C), 2 hr after gavage. 868 (E) The bioluminescence activity was quantified by determining the total flux (photons/sec; p/s). 869 n = 9 for each group; expressed as mean ± SD. P value was determined by paired t test. 870 (F-H) Mice were subjected to imaging prior to administration (E), then dissected in order to image 871 internal organs after vehicle (F) or AM095 (30 mg/kg, G) administration. Arrow, lymph node; Sp, 872 spleen; Lu, lung. 873 874 Figure 7. S1PR1/ ß-arrestin coupling in LPAR1 antagonist-treated lymph node 875 (A-E) Brachial lymph node sections from S1PR1-GFP signaling mice treated with vehicle or 876 AM095 were stained with B220 (red, B cell), CD8a (blue, T cell), and VEGFR3 (white, LEC) (A), 877 B220 (blue), CD11c (red, dendritic cell), and LYVE1 (white, LEC) (B,C), or CD169 (red, 878 macrophage), and LYVE1 (white) (D,E). LYVE1 + lymphatics were identified as subcapsular 879 sinuses if they were found in subcapsular space and contained B cells and dendritic cells. 880
Medullary sinuses contain CD169 + macrophages, and cortical sinuses are macrophage free (73). 881 (F) Mesenteric lymph node section was stained with VE-Cadherin (red), PECAM-1 (green), and 882 ERG (blue). The punctate and continuous junctions were indicated with arrowheads and asterisks, experiments; expressed as mean ± SD. P values were determined by two-way ANOVA followed 892 by Sidak's multiple comparisons test comparing "AUY954 + LPA" to AUY954 alone; *P ≤ 0.0001. 893
(E-H) HUVECs expressing LPAR1 were starved with 0.5% charcoal treated FBS for 2 hr, then 894 treated with 100 nM AUY954 and/ or LPA for 30 min. Cells were fixed and stained for VE-895 Cadherin (red) and p-MLC (green). F-actin and nuclei were stained with phalloidin (white) and The authors thank Drs. Hiroko Kishikawa, Yuji Shinjo, and Kumiko Makide for technical
